Yesterday's rebound, from a dip to the 50DMA to a close above the 200DMA, indicates that the stock has perhaps bottomed out in the near term. Over the past few days, dips to these two averages have been followed by a bounce back on the same or the next day. Thus the retracements are not lasting for too long. Repeated close above the 200DMA also signals that now the 0.90 level is the one to watch. A cross above that will take CDXC to the recent highs of about $1.2. All this will not happen too fast but if the results of Q4'12 beat expectations, the upswing may gather momentum. It is also possible that the management gives out more details of the BluScience sale deal with NutriSci International. The likely benefits of the $6M sale will help investors calculate the real effect of the deal on the company balance sheet. The deals comprises of $250K payment (already received), debt, stake in NutriSci and most importantly, royalty payments. If this cash trickle is expected to be substantial, then the other operations of company are likely to become smoother. The success will also encourage it to develop better products / compounds and the research & development efforts will become more robust. As the deal is likely to be closed within this month, the details should be out any time now. CDXC's future may change for the better and, consequently, the stock will also become stronger. What is interesting to note is the CDXC will retain the rights over its patented product pTeroPure pterostilbene and hence NutriSci will have to buy it from Chromadex for making BluScience. Selling of this product through NutriSci will help it reach hitherto untapped markets (SE Asia) and the cost of selling / distribution will come down substantially. Thus the royalty payment for CDXC may be more consistent.